*Editor’s Note (March 16, 2020): Our team of analysts’ are currently working to refresh this outlook in light of COVID-19 and uncertainty in the global economy. As we monitor these rapidly changing developments, visit our new Resource Hub, a centralized location with all of the latest insights and business implications surrounding COVID-19, designed to help executives navigate uncertainty and the resulting impacts on global business.

Disruptions to the healthcare status quo will continue to amplify through the remainder of 2020. Relentless pricing pressure in developed markets and emerging market growth will cause pharma and biotech firms to reconsider their global footprint, while vertical integration leveraging technology and digital health will force established participants to provide value beyond their core therapeutic focus.

Shifting international footprints will require careful evaluation, sizing, and prioritization of markets – whether they be geographic markets, therapeutic areas, or payer and patient segments for pharma and biotech companies. In a value-centric environment, traditional healthcare firms will need to consider partnerships and M&A to develop competencies outside their core therapeutic focus. In the short video below, FrontierView’s healthcare experts outline the key trends and business implications discussed in the 2020 Healthcare Outlook that executives in the pharma, biotech, payer and provider industries need to consider to remain ahead of the curve in 2020:

FrontierView’s Healthcare team is at the forefront of key trends impacting the industry. How can we help you deliver better outcomes for your business in 2020? Contact us to connect with a team member.

Fill out the form below to download the 2020 Healthcare Outlook.

*Editor’s note: This page was updated on January 6, 2020 to reflect current trends in the healthcare, pharma, and biotech industries.